본문으로 건너뛰기
← 뒤로

Reciprocal cancer risks between thyroid and breast cancer: a systematic review and meta-analysis.

메타분석 1/5 보강
Endocrine-related cancer 📖 저널 OA 34.8% 2022: 3/13 OA 2023: 7/19 OA 2024: 5/12 OA 2025: 19/50 OA 2026: 6/21 OA 2022~2026 2025 Vol.32(10)
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
787 patients were included in the meta-analysis of TC1-BC2 and showed an increased risk of BC after TC (SIR = 1.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
we demonstrated an increased risk of TC or BC as secondary malignancies.

Viola PP, Baumgarten MW, Varvaki Rados DR, Ribeiro L, Maia AL, Goemann IM

📝 환자 설명용 한 줄

Thyroid cancer (TC) and breast cancer (BC) are common in females, with growing evidence of their higher-than-expected co-occurrence.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value P < 0.01
  • 95% CI 1.2-1.6
  • 연구 설계 systematic review

이 논문을 인용하기

↓ .bib ↓ .ris
APA Viola PP, Baumgarten MW, et al. (2025). Reciprocal cancer risks between thyroid and breast cancer: a systematic review and meta-analysis.. Endocrine-related cancer, 32(10). https://doi.org/10.1530/ERC-24-0338
MLA Viola PP, et al.. "Reciprocal cancer risks between thyroid and breast cancer: a systematic review and meta-analysis.." Endocrine-related cancer, vol. 32, no. 10, 2025.
PMID 40985542 ↗
DOI 10.1530/ERC-24-0338

Abstract

Thyroid cancer (TC) and breast cancer (BC) are common in females, with growing evidence of their higher-than-expected co-occurrence. The purpose of this systematic review and meta-analysis was to evaluate the relationship between TC and BC and to examine the likelihood of developing BC after TC (TC1-BC2) and TC after BC (BC1-TC2). A systematic search was conducted in PubMed and Embase for articles with epidemiological evidence of TC and BC, published until 2024. For BC1-TC2 studies, subgroup analysis was performed on age at diagnosis and treatment type. The standardized incidence ratio (SIR) was used to calculate the risk of second primary malignancy. The MOOSE guidelines were followed, and the Newcastle-Ottawa scale was used to assess the quality of studies. Sixteen studies comprising 511,787 patients were included in the meta-analysis of TC1-BC2 and showed an increased risk of BC after TC (SIR = 1.4, 95% CI: 1.2-1.6, P < 0.01). Moreover, 28 studies with 2,486,870 patients were included for the BC1-TC2 meta-analysis and also demonstrated an increased risk of TC after BC (SIR = 1.5, 95% CI: 1.3-1.7, P < 0.01). The risk of TC was higher in BC patients under 50 (SIR = 1.8, 95% CI: 1.2-2.3) and in those treated with chemotherapy (SIR = 1.6, 95% CI: 1.5-1.7). Radiotherapy for BC was not linked to an increased risk of TC. Here, we demonstrated an increased risk of TC or BC as secondary malignancies. Furthermore, studies are needed to better understand this association and its implications for patient follow-up and management strategies.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반